Phase II study of intraperitoneal carboplatin with intravenous paclitaxel in patients with suboptimal residual epithelial ovarian or primary peritoneal cancer: A Sankai Gynecology Cancer Study Group Study

International Journal of Gynecological Cancer

Volumn 19, Issue 5, 2009, Pages 834-837

  Fujiwara, Keiichi ^a   Nagao, Shoji ^a   Kigawa, Junzo ^b   Noma, Jun ^c   Akamatsu, Nobuo ^d   Miyagi, Yasunari ^e   Numa, Fumitaka ^f   Okada, Makoto ^g   Aotani, Eriko ^h  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b TOTTORI UNIVERSITY   (Japan)

^c HIROSHIMA CITY HOSPITAL   (Japan)

^d HIMEJI RED CROSS HOSPITAL   (Japan)

^e Okayama Ofuku Clinic   (Japan)

^f Tokuyama Central Hospital   (Japan)

^g YAMAGUCHI RED CROSS HOSPITAL   (Japan)

^h KITASATO UNIVERSITY   (Japan)

Author keywords

Carboplatin; Intraperitoneal chemotherapy; Ovarian cancer; Phase II study; Suboptimal residual disease

Indexed keywords

CARBOPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT;

ARTHRALGIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LIVER DYSFUNCTION; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUTROPENIA; OVARY CARCINOMA; OVERALL SURVIVAL; PATIENT SATISFACTION; PERITONEUM CANCER; PHASE 2 CLINICAL TRIAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SENSORY NEUROPATHY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME; CANCER STAGING; COLLOID CARCINOMA; CYSTADENOCARCINOMA; ENDOMETRIUM TUMOR; INFUSION; INTRAVENOUS DRUG ADMINISTRATION; MAXIMUM TOLERATED DOSE; MORTALITY; OVARY TUMOR; PATHOLOGY; PERITONEUM TUMOR; PROGNOSIS; SURVIVAL RATE;

ADENOCARCINOMA, MUCINOUS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INFUSIONS, PARENTERAL; MAXIMUM TOLERATED DOSE; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; PERITONEAL NEOPLASMS; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 69449108435     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181a29dfe     Document Type: Article

References (15)

1. Fujiwara K, Armstrong D, Morgan M, et al. Principles and practice of intraperitoneal chemotherapy for ovarian cancer. Int J Gynecol Cancer. 2007;17:1-20.
2. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996;335:1950-1955.
3. Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standarddose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19:1001-1007.
4. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34-43.
5. Fujiwara K, Sakuragi N, Suzuki S, et al. First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up. Gynecol Oncol. 2003;90:637-643.
6. Ozols RF, Young RC, Speyer JL, et al. Phase I and pharmacological studies of adriamycin administered intraperitoneally to patients with ovarian cancer. Cancer Res. 1982;42:4265-4269.
7. Durand RE. Flow cytometry studies of intracellular adriamycin in multicell spheroids in vitro. Cancer Res. 1981;41:3495-3498.
8. West GW, Weichselbaum R, Little JB. Limited penetration of methotrexate into human osteosarcoma spheroids as a proposed model for solid tumor resistance to adjuvant chemotherapy. Cancer Res. 1980;40:3665-3668.
9. Nederman T, Carlsson J. Penetration and binding of vinblastine and 5-fluorouracil in cellular spheroids. Cancer Chemother Pharmacol. 1984;13:131-135.
10. Howell SB, Pfeifle CL, Wung WE, et al. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med. 1982;97:845-851.
11. Miyagi Y, Fujiwara K, Kigawa J, et al. Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal versus intravenous infusion of carboplatinVa Sankai Gynecology Study Group (SGSG) study. Gynecol Oncol. 2005;99:591-596.
12. Fujiwara K, Markman M, Morgan M, et al. Intraperitoneal carboplatinbased chemotherapy for epithelial ovarian cancer. Gynecol Oncol. 2005;97:10-15.
13. Los G, Verdegaal EM, Mutsaers PH, et al. Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy. Cancer Chemother Pharmacol. 1991;28:159-165.
14. Markman M, Reichman B, Hakes T, et al. Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancer. Gynecol Oncol. 1993;50:100-104.
15. Nagao S, Fujiwara K, Ohishi R, et al. Combination chemotherapy of intraperitoneal carboplatin and intravenous paclitaxel in suboptimally debulked epithelial ovarian cancer. Int J Gynecol Cancer. 2008; 18:1210-1214.